LOS ANGELES: Balmoral Funds LLC has acquired Wilbur-Ellis Nutrition, LLC, a leading provider of custom nutrition products for the Pet, Aquaculture and Livestock markets, from Wilbur-Ellis Holdings II, LLC. The newly independent company will operate under the historic brand name Rangen.
The acquisition includes the full Nutrition business of Wilbur-Ellis, encompassing product lines such as Rangen, Ametza, Emmert, Oxy-Gon, Oxy-Gold, and Oxy-Block, along with proprietary premixes, ingredient blends, sourcing services, and all associated operations.
Mark Essig, a veteran executive with more than 30 years of leadership experience, has been appointed CEO of Rangen. Essig emphasized the company’s legacy and technical expertise as key drivers for future growth. “Together with Balmoral’s support, we will accelerate innovation and growth across the Pet, Aquaculture, and Livestock markets,” he said.
Richard Levernier, Principal at Balmoral Funds and board member of Rangen, highlighted the company’s strong foundation and commitment to customer partnerships. “Rangen is well positioned to invest in capacity and innovation to support our customers’ growth,” Levernier said.
The transaction marks a strategic move by Balmoral to strengthen Rangen’s position in the animal nutrition industry, with a renewed focus on operational excellence, employee empowerment, and stakeholder collaboration.
Legal counsel for Balmoral was provided by Blank Rome LLP. Wilbur-Ellis was advised by Lazard and Pillsbury Winthrop Shaw Pittman LLP.